Belsomra vs Trazodone: Cost, Access, and Clinical Comparison

The Price Gap Between These Two Sleep Drugs Is Enormous

The single biggest difference between Belsomra and trazodone is cost. A 30-day supply of Belsomra 20 mg lists at approximately $450 to $500 without insurance, according to GoodRx pricing data as of early 2026. Trazodone 50 mg or 100 mg, the doses most commonly prescribed for insomnia, costs $4 to $15 at most pharmacies with a discount card and no insurance at all.

That price difference is not a rounding error. It is a 30-fold to 100-fold gap.

Belsomra (suvorexant) remains brand-only. Merck's patent exclusivity keeps generic manufacturers off the market until at least 2029. Trazodone lost patent protection decades ago, and dozens of generic manufacturers produce it. The FDA's Orange Book confirms no approved ANDA filings for suvorexant generics as of this writing.

For patients paying out of pocket, trazodone is one of the cheapest prescription sleep aids in the United States. Belsomra is one of the most expensive. That gap alone drives prescribing decisions for millions of patients, regardless of what clinical trials show about relative efficacy.

Insurance and Formulary Access Differ Sharply

Trazodone sits on Tier 1 (preferred generic) of nearly every commercial, Medicare Part D, and Medicaid formulary in the country. No prior authorization is required. No step therapy. No quantity limits in most plans. A physician writes the prescription, and the pharmacist fills it the same day.

Belsomra occupies Tier 3 (preferred brand) or Tier 4 (non-preferred brand) on most formularies, and some plans exclude it entirely. The Centers for Medicare & Medicaid Services formulary search tool shows that the majority of Medicare Part D plans require prior authorization for suvorexant, often demanding documented failure of at least one generic alternative first. That step-therapy requirement frequently means the patient must try trazodone, zolpidem, or eszopiclone before Belsomra is covered.

Even with commercial insurance, out-of-pocket copays for Belsomra typically run $40 to $75 per month after plan contributions. Merck offers a savings card that can reduce this for commercially insured patients, but Medicare and Medicaid beneficiaries are ineligible for manufacturer copay assistance under federal anti-kickback rules [1].

The access story is clear: a patient with no insurance, Medicaid, or a high-deductible plan will almost certainly end up on trazodone or another generic. Belsomra is functionally available only to patients with mid-tier or better commercial insurance who are willing to manage prior authorization paperwork with their prescriber.

How the Drugs Actually Work: Two Different Mechanisms

These medications reach the same destination (sleep) through completely different pharmacological routes. Belsomra is a dual orexin receptor antagonist (DORA). It blocks the binding of orexin-A and orexin-B to OX1R and OX2R receptors in the lateral hypothalamus, suppressing the wake-promoting signal rather than forcing sedation [2]. The orexin system was identified in 1998 by de Lecea and Sakurai as a primary regulator of wakefulness and arousal, and narcolepsy was later linked to orexin neuron destruction.

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) originally developed and approved for major depressive disorder. At low doses (25 mg to 100 mg), its sedating properties come primarily from antagonism of 5-HT2A serotonin receptors and histamine H1 receptors, with less serotonin reuptake inhibition than at antidepressant doses (150 mg to 300 mg) [3]. The sleep effects are essentially a side effect repurposed as the main indication.

This mechanistic difference matters clinically. Belsomra reduces wakefulness without substantially altering sleep architecture. Trazodone increases slow-wave sleep (stages N3) more than most alternatives, which some clinicians consider a benefit for restorative sleep, though the evidence base for that claim remains thin.

What the Clinical Trials Show (and Don't Show)

No published randomized controlled trial has compared Belsomra head-to-head against trazodone. All comparisons require cross-trial inference, which carries significant limitations.

Belsomra's key data comes from the Herring et al. phase III trial published in The Lancet Neurology in 2014 (N=3,291). Suvorexant 40 mg and 20 mg were compared against placebo over 12 months. At the FDA-approved dose range (10 mg to 20 mg), suvorexant reduced subjective time to sleep onset by approximately 8 to 10 minutes versus placebo and increased total sleep time by roughly 16 to 25 minutes. Polysomnography-measured wake after sleep onset (WASO) improved by about 22 minutes at month one [2]. Effect sizes were statistically significant but modest in absolute terms.

The FDA initially rejected the 40 mg dose over next-morning impairment concerns and approved only 10 mg and 20 mg. Dr. Russell Katz, then-director of the FDA's Division of Neurology Products, noted during the 2013 advisory committee meeting: "The efficacy seen at the lower doses is real, but it is not large."

Trazodone's insomnia evidence is far weaker from a trial-design standpoint. The most cited study is Mendelson's 2005 review in The Journal of Clinical Psychiatry, which examined the available controlled data and concluded that randomized evidence supporting trazodone for primary insomnia was "extremely limited" despite its widespread off-label use [3]. A placebo-controlled trial by Walsh et al. (2000) studied trazodone 50 mg in primary insomnia patients for two weeks and found improved sleep during week one but not week two, raising durability questions [4].

Despite this evidence gap, trazodone is the most prescribed medication for insomnia in the United States. An analysis using National Ambulatory Medical Care Survey data estimated that trazodone accounted for roughly 5.5 million insomnia-related prescriptions annually as of the early 2020s [5]. Prescribers choose it because it is cheap, unscheduled, and perceived as low-risk, not because the RCT data compels them.

Side Effect Profiles: Different Risks for Different Patients

Belsomra's most common adverse effects in clinical trials were somnolence (7% vs. 3% placebo), headache, and abnormal dreams. The drug carries a class warning about complex sleep behaviors (sleepwalking, sleep-driving), though the incidence in trials was low. Next-morning drowsiness was dose-dependent; at 20 mg, approximately 2% to 3% of patients in the Herring trial reported residual impairment [2]. Belsomra is classified as Schedule IV by the DEA due to theoretical abuse potential, although real-world reports of suvorexant abuse are rare according to post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS).

Trazodone's side effect profile differs substantially. The most frequent complaints at sleep doses are morning grogginess, dry mouth, dizziness, and orthostatic hypotension. Trazodone carries a rare but well-known risk of priapism (prolonged, painful erection) in male patients, estimated at roughly 1 in 6,000 to 1 in 8,000 male patients, a risk that requires emergency urological intervention if it occurs [6]. Cardiac effects include modest QTc prolongation at higher doses, which is clinically relevant in patients with baseline conduction abnormalities or those taking other QT-prolonging drugs.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for insomnia pharmacotherapy recommended suvorexant (weak recommendation, moderate-quality evidence) but did not include trazodone among its recommended agents due to insufficient evidence [7]. That guideline distinction matters: Belsomra has a recommendation; trazodone does not.

Who Is the Right Patient for Each Drug?

Clinical decision-making between these two drugs depends on four variables: cost sensitivity, comorbidities, scheduling concerns, and prior treatment history.

Trazodone is the practical first-line choice for patients with insomnia who also have comorbid depression or anxiety (the antidepressant properties add benefit at higher doses), patients on tight budgets or high-deductible plans, patients who need an unscheduled medication (e.g., those with substance use histories where Schedule IV drugs are undesirable), and patients whose providers want to avoid prior authorization delays.

Belsomra may be preferred for patients who failed generic sleep aids including trazodone, patients concerned about anticholinergic or antihistaminic side effects (Belsomra lacks both), male patients who consider priapism risk unacceptable, older adults where the AASM specifically recommends orexin antagonists over benzodiazepine receptor agonists [7], and patients whose insurance covers it without excessive out-of-pocket cost.

Dr. Andrew Krystal, a sleep medicine researcher at UCSF, has stated in clinical reviews: "The orexin antagonists represent a fundamentally different approach to treating insomnia. They reduce wake drive rather than inducing sedation, which may translate to a more physiologic sleep pattern."

Switching Between Belsomra and Trazodone

No washout period is pharmacologically required when switching from one to the other. Belsomra has a half-life of approximately 12 hours; trazodone's half-life is 5 to 9 hours. Both clear within two to three days of the last dose.

The standard clinical approach is straightforward: discontinue the first medication, start the second the following evening. Some clinicians prefer a one-night gap, though this is based on caution rather than pharmacokinetic necessity.

Patients switching from Belsomra to trazodone for cost reasons should be counseled about the different side effect profile, particularly morning sedation (which may be more pronounced with trazodone at equivalent sleep-promoting effect levels) and orthostatic hypotension. Patients switching from trazodone to Belsomra typically do so after trazodone failure and should know that Belsomra's effect size, while consistent, is modest in absolute terms.

Concurrent use of both drugs is not recommended. Combining an orexin antagonist with a sedating antidepressant increases the risk of excessive somnolence, and no efficacy data supports the combination for insomnia.

Trazodone's Off-Label Status Matters More Than You Think

The fact that trazodone has never received FDA approval for insomnia is not merely a regulatory footnote. It means no manufacturer has submitted the full Phase III dossier required for an insomnia indication, including long-term safety data, morning-after driving studies, and abuse-liability assessments that FDA now expects. When the FDA approved suvorexant in 2014, it required Merck to conduct specific next-day impairment testing and post-marketing safety studies.

Trazodone has none of that infrastructure behind it for the insomnia indication. Prescribers extrapolate from depression-trial safety data and decades of clinical experience, which is substantial but not equivalent to a formal insomnia-specific approval package.

For patients, this distinction affects insurance appeals, disability documentation, and legal liability. A prescriber writing trazodone for insomnia is prescribing off-label, which most malpractice frameworks permit when supported by clinical consensus. A prescriber writing Belsomra for insomnia is prescribing on-label. Both are standard of care, but the regulatory scaffolding differs.

The Generic Horizon for Belsomra

Merck's composition-of-matter patent on suvorexant (U.S. Patent No. 8,329,739) has an expected expiry date in the 2029 to 2031 window depending on pediatric exclusivity extensions and any patent-term adjustments. Several generic manufacturers have filed Paragraph IV certifications with the FDA, signaling intent to launch generic versions upon patent expiration [8].

When generic suvorexant does arrive, the cost comparison will shift dramatically. Generic orexin antagonists could price at $15 to $40 per month based on typical generic pricing patterns for Schedule IV neuropsychiatric drugs, making the cost difference between suvorexant and trazodone a factor of 2 to 3 rather than the current 30 to 100.

Until that happens, trazodone remains the default choice for cost-constrained patients. Providers should document trazodone trial and failure if they plan to pursue prior authorization for Belsomra, as most payers require this step.

Newer Orexin Antagonists Add Context to This Comparison

Belsomra is no longer the only DORA on the market. Quviviq (daridorexant), approved by the FDA in January 2022, showed efficacy at 25 mg and 50 mg doses in the VIVALDI-1 and VIVALDI-2 trials with what some reviewers consider a cleaner next-day profile than suvorexant [9]. Daridorexant's shorter half-life (approximately 8 hours vs. suvorexant's 12 hours) may reduce next-morning residual effects.

Quviviq is also brand-only and similarly expensive ($400 to $450/month retail). For the cost-and-access comparison against trazodone, it occupies the same bracket as Belsomra: effective but expensive and access-limited. The clinical relevance is that if a patient fails or cannot tolerate Belsomra, daridorexant is an alternative within the same class before reverting to older, cheaper agents. Lemborexant (Dayvigo), another DORA approved in 2019, provides a third option in this class at a comparable price point [10].

The AASM's 2023 updated guidance acknowledged the growing role of orexin antagonists and explicitly stated that DORAs are "recommended for sleep-onset and sleep-maintenance insomnia" with moderate-strength evidence, placing them alongside Z-drugs but above trazodone in the evidence hierarchy [7].

Patients who need a sleep medication for six months or longer should have a cost conversation early. At $450/month, a year of Belsomra costs $5,400 out of pocket. A year of trazodone costs $48 to $180.